Merck Dividendi e riacquisti
Criteri Dividendo verificati 4/6
Merck è una società che paga dividendi con un rendimento attuale di 2.23%. La prossima data di pagamento è il 7th October, 2026 con una data di stacco della cedola di 15th September, 2026.
Informazioni chiave
2.2%
Rendimento del dividendo
1.2%
Rendimento del riacquisto
| Rendimento totale per gli azionisti | 3.4% |
| Rendimento futuro dei dividendi | 2.4% |
| Crescita dei dividendi | 6.5% |
| Prossima data di pagamento dei dividendi | 07 Oct 26 |
| Data di stacco del dividendo | 15 Sep 26 |
| Dividendo per azione | n/a |
| Rapporto di remunerazione | 259% |
Aggiornamenti recenti su dividendi e riacquisti
Recent updates
Aggiornamento narrativa • Aug 12
MRK: Pipeline Execution And Patent Cliff Response Will Shape Future Earnings Balance
Merck's updated analyst price target framework now points to a fair value of $136.85, up from $132.78. Analysts link this shift to a series of higher Street targets that emphasize the company's dividend profile, pipeline progress, and M&A optionality.
Aggiornamento narrativa • Jul 29
MRK: Pipeline Execution And Policy Headwinds Will Restrain Multiple Expansion
Merck's updated analyst price target reflects a modest fair value move to about $108, with analysts pointing to refreshed pipeline assumptions, sector re-rating, and multiple expansion as key drivers behind the change. Analyst Commentary Recent commentary on Merck highlights a mix of optimism around the pipeline and sector setup alongside a more cautious tone on execution risks, earnings durability, and regulatory overhangs.Seeking Alpha • Jul 17
Merck: 'Strong Buy' Lipfendra FDA First And Continued Oncology Expansions
Summary Merck & Co., Inc. maintains a Strong Buy rating, driven by robust oncology expansion and the launch of LIPFENDRA, the first oral PCSK9 inhibitor for hypercholesterolemia. The company's oncology pipeline advances with FDA acceptance of four regulatory filings, including ifinatamab deruxtecan, and strategic acquisitions like Terns to counter KEYTRUDA's 2028 patent expiry. LIPFENDRA targets statin-treated patients needing further LDL-C reduction, with peak sales potential estimated at $5 billion by 2034, strengthening MRK's cardiometabolic portfolio. Q1 2026 revenues grew 5% to $16.3B, led by Oncology and Animal Health, but risks remain around KEYTRUDA patent loss, new product launches, and regulatory outcomes. Read the full article on Seeking AlphaAggiornamento narrativa • Jul 14
MRK: Oncology Pipeline And Patent Cliff Responses Will Shape Earnings Balance
Merck's updated analyst price target moves higher by a few dollars, reflecting modestly higher fair value estimates to $132.78, alongside generally supportive analyst views around the company's Q2 setup, sector fund flows, and long term pipeline assumptions. Analyst Commentary Analysts covering Merck are broadly constructive ahead of the upcoming Q2 report, with most recent research focused on price target updates, the earnings setup, and how the pipeline and regulatory backdrop could shape the stock's risk and reward profile.
Aggiornamento narrativa • Jun 30
MRK: Late-Stage Pipeline And Oncology Approvals Will Support Higher Future P E Multiple
Analysts have raised the Merck fair value estimate to $155 from $150, pointing to higher long term earnings expectations and multiple expansion, as reflected in recent Street price target increases to as high as $155. Analyst Commentary Recent Street research on Merck reflects a cluster of constructive views, with several bullish analysts lifting price targets and highlighting long term earnings potential.Aggiornamento narrativa • Jun 15
MRK: Terns Acquisition Execution And Bidding Risk Will Constrain Future Upside
Analysts have nudged their price targets for Merck higher by about $3 to $15 in recent research, supporting a modest increase in the fair value estimate to $101.68. This reflects updated profit margin assumptions and a slightly lower future P/E, along with adjustments to revenue growth expectations and discount rates.Aggiornamento narrativa • Jun 01
MRK: Oncology Pipeline And Terns Deal Will Shape Future Earnings Balance
Analysts have nudged their average price targets on Merck higher by $3 to $15 in recent weeks, citing updated views on the company’s oncology pipeline, the Terns Pharmaceuticals deal, and specific assets like Sac TMT that some expect could materially influence Merck’s long term earnings profile. Analyst Commentary Recent Street research around Merck clusters around two main themes, the potential of key pipeline assets like Sac TMT and TERN-701, and how recent study outcomes and deal activity could affect execution risk and valuation.
Aggiornamento narrativa • May 21
Merck (MRK) – Expands Oncology Leadership with New Clinical Data at ASCO 2026
Announcement Overview Analyst: Qudus Adebara (Founder, Wane Investment House) Merck & Co., Inc. (“Merck” or “the Company”), known as MSD outside the United States and Canada, has announced that it will present more than 100 abstracts spanning over 25 cancer types at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting , scheduled for May 29 – June 2, 2026.Aggiornamento narrativa • May 19
Merck Completes Acquisition of Terns Pharmaceuticals
Strengthening Hematology Pipeline with Breakthrough CML Therapy Candidate TERN-701 Analyst: Qudus Adsebara (Founder, Wane Investment House) Transaction Overview Merck & Co Inc (NYSE: MRK), known as MSD outside the United States and Canada, has successfully completed the acquisition of Terns Pharmaceuticals Inc following the conclusion of its cash tender offer and merger process. The acquisition reinforces Merck’s strategy of expanding its oncology and hematology pipeline through science-driven and value-enhancing business development initiatives.Aggiornamento narrativa • May 17
MRK: Oncology Pipeline And Terns Deal Will Shape Forward Risk Balance
Merck's analyst fair value estimate is now $129.74. Analysts link this adjustment and modestly higher assumed revenue growth and P/E multiples to recent price target increases from firms such as Wells Fargo, UBS, JPMorgan, Citi, Morgan Stanley, RBC, and Barclays following pipeline updates and the Terns acquisition.Articolo di analisi • May 11
Merck's (NYSE:MRK) Soft Earnings Don't Show The Whole Picture
Shareholders appeared unconcerned with Merck & Co., Inc.'s ( NYSE:MRK ) lackluster earnings report last week. Our...Aggiornamento narrativa • May 02
MRK: Oncology Reorg And Deals For Targeted Therapies Will Support Higher P E Multiple
Analysts nudged the Merck price target higher by a few dollars per share, reflecting updated expectations for slightly lower revenue growth, a modestly higher profit margin, and a somewhat lower future P/E multiple, supported by recent research commentary on the pipeline and business development moves. Analyst Commentary Recent research has tilted positive around Merck, with several large firms adjusting their models and price targets to reflect updated views on the pipeline, partnered programs, and business development activity.Aggiornamento narrativa • Apr 19
Merck & Co., Inc. – Tender Offer for Terns Pharmaceuticals, Inc. (Full Acquisition Transaction)
Author: Qudus Adebara (Founder of Wane Investment House) Transaction Overview Merck & Co., Inc. (known as MSD outside the U.S. and Canada) has formally commenced a cash tender offer to acquire all outstanding shares of Terns Pharmaceuticals, Inc., following the signing of a definitive agreement on March 25, 2026.Aggiornamento narrativa • Apr 18
MRK: Oncology Reorg And Pipeline Deals Will Support Higher Future P E Multiple
Analysts have lifted their Merck price targets by up to the mid double digits in recent weeks, citing higher modeled revenue growth, slightly stronger profit margins, and updated views on future P/E multiples as Merck advances its pipeline and business development moves. Analyst Commentary Recent Street research on Merck has been broadly constructive, with a cluster of price target revisions and fresh initiations pointing to confidence in the company’s execution, pipeline progress, and M&A activity.Aggiornamento narrativa • Apr 04
MRK: M&A Execution Risks Around Terns And Revolution Will Restrain Future Upside
Analysts have nudged Merck's fair value estimate higher to approximately $101.30, reflecting updated assumptions for slightly stronger revenue growth, a modestly higher profit margin, and a marginally lower future P/E. This view is supported by a wave of recent price target increases into the $130 to $150 range and fresh Outperform or Overweight initiations on the stock.Aggiornamento narrativa • Mar 21
MRK: Pipeline Readouts And Oncology Reorg Will Support Higher Future P E Multiple
The analyst price target for Merck has been reset from $136 to $150. This reflects analysts' updated assumptions for modestly higher revenue growth, a stronger profit margin profile, and a slightly lower future P/E multiple, supported by recent research that highlights potential upside from Sac TMT, upcoming launches, and key Phase 3 readouts.Aggiornamento narrativa • Mar 06
MRK: Keytruda Cliff And M&A Uncertainty Will Likely Curb Long Term Upside
Analysts have lifted their Merck fair value estimate from $83.00 to about $101.04, pointing to broad price target hikes across the Street and citing confidence in upcoming product launches, Phase 3 readouts, and management's approach to the Keytruda loss of exclusivity. Analyst Commentary Recent research coverage on Merck has tilted positive, with several firms lifting price targets and starting the stock with favorable ratings.Aggiornamento narrativa • Feb 20
MRK: Pipeline Readouts And Gardasil Policy Shifts Will Shape Forward Risk Balance
Analysts have lifted their Merck fair value estimate from $115.11 to $124.88, citing a higher expected future P/E, modestly higher projected revenue growth, and a series of recent price target hikes that highlight confidence in upcoming launches and data readouts. Analyst Commentary Recent Street research around Merck points to a generally constructive tone, with many firms adjusting ratings and price targets in a way that supports a higher fair value, while still flagging a few execution and policy watchpoints for investors to track.Aggiornamento narrativa • Feb 06
MRK: Rising Confidence In Pipeline Execution To Support Richer Future P E Multiple
Analysts have nudged our Merck fair value estimate higher to $136, reflecting a higher average price target across firms such as Scotiabank, Goldman Sachs, BMO, BofA, Citi, Wells Fargo, Bernstein, Cantor Fitzgerald, TD Cowen, and others, who cite stronger top line expectations, updated margin assumptions, and a richer future P/E multiple. Analyst Commentary Across recent research, bullish analysts are largely aligned in their view that Merck is executing well enough to support higher valuation assumptions.Aggiornamento narrativa • Jan 23
MRK: M&A Pipeline And Gardasil Policy Shifts Will Shape Future Risk Balance
Analysts lifted their Merck fair value estimate by about $8.50 to $115.11 per share as they factor in a higher future P/E multiple, recent price target increases from several firms, and growing confidence in the company being added to BofA's "US 1 List." Analyst Commentary Recent research on Merck gives you a mix of confidence in the company’s execution and some clear areas to watch. Here is how the current commentary breaks down.Aggiornamento narrativa • Jan 09
MRK: Cidara Flu Deal Will Likely Highlight Overstated Long Term Hopes
Narrative Update The analyst price target for Merck has moved higher to a range of about $105 to $135. Analysts point to sector re-ratings, recent upgrades to Outperform, and confidence in the company’s product pipeline and deal activity as key drivers of their updated views.Prossimo pagamento dei dividendi
Stabilità e crescita dei pagamenti
Recupero dei dati sui dividendi
Dividendo stabile: I dividendi per azione di MRK sono rimasti stabili negli ultimi 10 anni.
Dividendo in crescita: I pagamenti dei dividendi di MRK sono aumentati negli ultimi 10 anni.
Rendimento dei dividendi rispetto al mercato
| Merck Rendimento dei dividendi rispetto al mercato |
|---|
| Segmento | Rendimento dei dividendi |
|---|---|
| Azienda (MRK) | 2.2% |
| Fondo del 25% del mercato (US) | 1.3% |
| Top 25% del mercato (US) | 4.0% |
| Media del settore (Pharmaceuticals) | 1.8% |
| Analista previsionale (MRK) (fino a 3 anni) | 2.4% |
Dividendo notevole: Il dividendo di MRK ( 2.23% ) è più alto rispetto al 25% inferiore dei pagatori di dividendi nel mercato US ( 1.33% ).
Dividendo elevato: Il dividendo di MRK ( 2.23% ) è basso rispetto al 25% dei maggiori pagatori di dividendi nel mercato US ( 3.99%.
Distribuzione degli utili agli azionisti
Copertura degli utili: Con il suo elevato payout ratio ( 259.4% ), i pagamenti dei dividendi di MRK non sono ben coperti dagli utili.
Pagamenti in contanti agli azionisti
Copertura del flusso di cassa: Grazie al suo ragionevole cash payout ratio ( 52.2% ), i pagamenti dei dividendi di MRK sono coperti dai flussi di cassa.
Scoprire le società che pagano dividendi forti
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/08/19 04:12 |
| Prezzo dell'azione a fine giornata | 2026/08/19 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Merck & Co., Inc. è coperta da 49 analisti. 23 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| David Toung | Argus Research Company |
| Charles Butler | Barclays |
| Emily Field | Barclays |